Phase II randomised trial of raltitrexed–oxaliplatin vs raltitrexed–irinotecan as first-line treatment in advanced colorectal cancer

Por Feliu, J, Castañón, C, Salud, A, Mel, J R, Escudero, P, Pelegrín, A, López-Gómez, L, Ruiz, M, González, E, Juárez, F, Lizón, J, Castro, J, González-Barón, M
Publicado em 2005

Irinotecan plus raltitrexed as first-line treatment in advanced colorectal cancer: a phase II study

Por Feliu, J, Salud, A, Escudero, P, López-Gómez, L, Pericay, C, Castañón, C, de Tejada, M R López, Rodríguez-García, J M, Martínez, M P, Martín, M Sanz, Sánchez, J J, Barón, M González
Publicado em 2004

Docetaxel combined with irinotecan or 5-fluorouracil in patients with advanced oesophago-gastric cancer: a randomised phase II study

Por Roy, A, Cunningham, D, Hawkins, R, Sörbye, H, Adenis, A, Barcelo, J-R, Lopez-Vivanco, G, Adler, G, Canon, J-L, Lofts, F, Castanon, C, Fonseca, E, Rixe, O, Aparicio, J, Cassinello, J, Nicolson, M, Mousseau, M, Schalhorn, A, D'Hondt, L, Kerger, J, Hossfeld, D K, Garcia Giron, C, Rodriguez, R, Schoffski, P, Misset, J-L
Publicado em 2012